An FDA Advisory Panel Voted to Ease Restrictions on 6 Controversial Peptides—Here’s What That Means

28.07.2026, 16:59 allure.com

The long-awaited meeting to decide the future of a handful of injectable peptides previously restricted by the Food & Drug Administration (FDA) was held on July 23 and 24, and now we know more about what to expect from this emerging category.

The Meeting of the Pharmacy Compounding Advisory Committee (PCAC) met to discuss seven different injectable peptide varieties, including BPC-157, which is commonly used for post-workout recovery and muscle repair; KPV, which is said to calm skin inflammation; and Epitalon, which is said to have aging, longevity, and sleep benefits.

The advisory panel voted to recommend that the FDA loosen its restrictions on six of the seven peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. (It’s worth noting that the committee was heavily made up of pro-peptide individuals, including doctors, and it’s also worth noting that the FDA itself advised against loosening restrictions, saying there’s just not enough clinical evidence yet.) “Approved” peptides are thus eligible to be moved to the Section 503A Bulk List, which means compounding pharmacies could legally prepare said peptides for patients—with a valid prescription and specific quality and testing standards. It does not mean, however, that they become FDA approved.

As Allure previously reported, a group of 14 peptides that were previously banned under the Biden administration came up for debate in early 2026, in part due to their increasing popularity, and how quickly and relatively easy they became to procure online, where they are often purchased on what is called the “gray market.” Despite the fact that these peptides were restricted, and thus technically should not be sold, there’s a loophole that has made them available for purchase; they’re labeled as “for research purposes only,” which allows consumers to get around the restrictions. David J. Holt, attorney and owner of Holt Law, a health-care business law firm in Minnesota and California, previously likened enforcement to a game of “Whack-a-Mole,” with patient demand “greatly [outweighing] the federal government's appetite to enforce.”

While the July meetings only discussed seven of the 14 in question, the pro-peptide vote has lent a little more clarity about the future of injectable peptides in the health, wellness, and beauty industries. Peptide evangelists will tell you that the compounds can do pretty much everything; there’s even one called Melanotan II, or the “Barbie drug,” that promises to make you tan without the need for the sun or a tanning bed. (We have some feelings about that.)

But that doesn’t mean you’ll be seeing BPC-157 “legally” for sale at your local pharmacy tomorrow. There’s another important hurdle the peptides must go through, and it’s a big one: the FDA itself. “The recent 8-6 vote recommending BPC-157 and others for the 503A Bulks List is definitely a milestone for the wellness space,” explains Holt. “But it is important to clarify a common misconception; the FDA itself hasn't formally loosened restrictions yet.” The vote came from the PCAC, not the FDA, and “their recommendation is strictly advisory, not legally binding.”

According to Holt, “nothing changes” for consumers right now simply because the PCAC’s vote is an advisory one. As he explains, the next step rests with the FDA, which must decide whether to accept the committee's recommendation or not. If the FDA agrees to it, they have to initiate what is called a “formal notice-and-comment” rulemaking process, which Holt says generally takes well over a year. “Until that process officially concludes and BPC-157 is formally placed on the 503A Bulks List, consumers should understand that the peptide remains highly restricted,” he says. (This would apply to any of the six peptides discussed in the meeting.) “Any clinics currently claiming the peptide is ‘FDA approved’ or fully cleared for commercial human use are making legally false statements. Our social media feeds are already blowing up with incorrect characterizations of the outcome.”

Dustin Robinson, an attorney and founding partner of LumaLex Law, advises businesses in emerging health sectors, including peptides. He says that there is another “much faster” option that could be used in this case: enforcement discretion. “The FDA has a long-standing practice of sorting nominated ingredients into categories, and for the most favorable category it generally says it will not take action against a pharmacy that compounds with that ingredient while the formal process plays out, as long as the pharmacy meets the other legal conditions,” he explains.

If the PCAC recommends a peptide be placed on the 503A Bulk List and the FDA extends that discretion, he says, pharmacies could begin compounding it “well before” the rule is finalized. But Robinson says it’s important to note that the enforcement discretion is not automatic; it’s up to the FDA, and “right now, these specific peptides sit outside it.” The biggest risk to this potential pathway, Robinson explains, is reporting of adverse events, which the FDA describes as “any undesirable experience associated with the use of a medical product in a patient.” Should an adverse event happen, Robinson says it could “negatively impact or delay the rulemaking process.”

As the FDA pointed out in their official meeting recommendation to keep the peptides under their current restrictions, these peptides simply don’t have adequate clinical data behind them; the organization cited a lack of clinical and non-clinical safety information, human data, and evidence of efficacy as reasons why they recommend the peptides remain off the 503A Bulks list. “Most of these compounds still lack robust clinical data proving their safety and long-term efficacy,” Jeffrey Lee, MD, a board-certified plastic surgeon in Boston, previously told Allure. “At this stage, much of what’s circulating is anecdotal: people reporting personal use without clear, evidence-based conclusions about risks or side effects.” In addition, peptides are often marketed for a variety of wellness benefits, from joint and muscle repair to sleep, but for the purposes of the July meetings they were evaluated for specific purposes. For example, BPC-157 was evaluated as a treatment for ulcerative colitis, not workout recovery.

The outcome of the meeting also opens up discussion around the legality of acquiring peptides from a compounding pharmacy, medspa, or the gray market. Purchasing peptides from an unregulated online source is risky for many reasons, including potential contamination and injecting an unregulated, untested substance into your body. As reported by Time, one of the committee members, Dr. Haleem Mohammed, chief medical officer of the telehealth company Gameday Men’s Health, said he voted yes because he felt opening up access to the peptides was safer for patients than buying them on the gray market. “As a physician, I have to make sure that I'm keeping patients as safe as possible. That's my mandate, right? Do no harm,” he shared during the meeting. “So when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? And that's why I lose sleep at night.”

If the peptides are approved and moved to the 503A list, Holt says this would “create a legitimate, regulated pathway for state-licensed compounding pharmacies to produce these therapies for individual patients based on a valid prescription.” Medspas, longevity clinics, and telehealth organizations could “finally pivot away from the gray-market sourcing of ‘research use-only chemicals,’” he explains, and instead prescribe pharmaceutical-grade ingredients through a legal pathway. But the biggest immediate risk, he says, is “premature commercialization,” as clinics could misinterpret the advisory vote and start marketing the peptides before the FDA makes its decision—which could end in warning letters, frozen accounts, and “severe disciplinary action” from state pharmacy boards. If the peptides are not added to the 503A list, any provider offering them is likely using a questionable supply chain, like the gray market.

Koehl Robinson, CEO of telehealth company Celia RX, said she’s feeling “encouraged” by the outcome. (She was not a member of the PCAC.) “Getting seven peptides in front of the PCAC at all is a meaningful step. For years this category has existed in a gray zone where patient demand and clinical interest have far outpaced any formal regulatory review.”

As for how the general public feels about peptides, Koehl Robinson says she thinks the meetings are instrumental in shifting their view of the technology. “Public opinion on peptides right now is split between ‘miracle compound’ hype on one side and blanket skepticism on the other, and neither is doing patients any favors,” she explains.

Celia RX is launching its own 503A compounding pharmacy so they can control quality “rather than depending on a patchwork of suppliers with inconsistent standards,” says Koehl Robinson. Peptides produced by the facility will be run through Celia’s compliance and clinical protocols, which includes “physician review criteria, dosing standards, batch-level testing, certificates of authenticity [COAs,] and full traceability from raw material to prescription,” she shares.”It’s not a light switch, but it’s the difference between a patient getting something from an unregulated gray-market source and getting it from a licensed U.S. pharmacy with real oversight and sourcing integrity behind it.” Of the six peptides discussed, she’s most interested in BPC-157, KPV, and Epitalon, and says if they cleared review, Celia would move “quickly” to offer them.

But Jay Campbell, founder of BioLongevity Labs, a manufacturer of research-grade peptides, remains skeptical that the outcome is a real positive for peptide access. “This might sound counterintuitive, but while this decision loosens the restrictions on paper, it doesn't loosen anything in a way that helps most p